Abstract

63 Long-term outcomes following RIC HSCT for MDS with fludarabine, busulphan and alemtuzumab

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call